Benchmark analyst Robert Wasserman reiterated a Hold rating and $75.00 price target on Halozyme Therapeutics (NASDAQ: HALO).The analyst commented, "Halozyme ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE